Machine perfusion in organ transplantation: A tool for ex-vivo graft conditioning with mesenchymal stem cells?

Current Opinion in Organ Transplantation

Volumn 18, Issue 1, 2013, Pages 24-33

  Van Raemdonck, Dirk ^a,b   Neyrinck, Arne ^c   Rega, Filip ^d   Devos, Timothy ^e   Pirenne, Jacques ^f  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c Division of Anesthesiology and Algology   (Belgium)

^d Cardiac Surgery   (Belgium)

^e Department of Microbiology and Immunology   (Belgium)

^f REGA INSTITUTE   (Belgium)

Author keywords

ex vivo treatment; machine perfusion; mesenchymal stem cells; organ transplantation

Indexed keywords

BASILIXIMAB;

ACUTE KIDNEY FAILURE; ACUTE LUNG INJURY; ADAPTIVE IMMUNITY; EX VIVO STUDY; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; KIDNEY PERFUSION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LUNG PERFUSION; LUNG TRANSPLANTATION; MACHINE PERFUSION; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; ORGAN PERFUSION; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; REPERFUSION INJURY; RESUSCITATION; REVIEW;

ANIMALS; HEART; HUMANS; KIDNEY; LIVER; LUNG; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MODELS, ANIMAL; ORGAN PRESERVATION; ORGAN PRESERVATION SOLUTIONS; PANCREAS; PERFUSION;

EID: 84872897633     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32835c494f     Document Type: Review

References (91)

1. Ortega F. Organ transplantation in the 21st century. Adv Exp Med Biol 2012; 741:13-26.
2. Pirenne J. Time to think out of the (ice) box. CurrOpin Organ Transplant 2010; 15:147-149.
3. Jochmans I, Moers C, Ploeg R, Pirenne J. To perfuse or not to perfuse kidneys donated after cardiac death. Am J Transplant 2011; 11:409-410.
4. Monbaliu D, Liu Q, Libbrecht L, et al. Preserving morphology and evaluating quality of liver grafts by hypothermic machine perfusion, a proof of concept study using discarded human livers. Liver Transplant 2012; DOI: 10.1002/lt.23550.
5. Vogel T, Brockmann JG, Friend PJ. Ex-vivo normothermic liver perfusion. Curr Opin Organ Transplant 2010; 15:167-172.
6. Yeung JC, Cypel M, Machuca TN, et al. Physiologic assessment of the ex vivo donor lung fortransplantation. J Heart Lung Transplant 2012; 31:1120-1126.
7. Groen H, Moers C, Smits JM, et al. Cost-effectiveness of hypothermic machine perfusion versus static cold storage in renal transplantation. Am J Transplant 2012; 12:1824-1830.
8. Balfoussia D, Yerrakalva D, Hamaoui K, Papalois V. Advances in machine perfusion graft viability assessment in kidney, liver, pancreas, lung, and heart transplant. Exp Clin Transplant 2012; 10:87-100.
9. Schold JD, Kaplan B, Howard RJ, et al. Are we frozen in time? Analysis of the utilization and efficacy of pulsatile perfusion in renal transplantation. Am J Transplant 2005; 5:1681-1688.
10. Moers C, Smits JM, Maathuis MH, et al. Machine perfusion or cold storage in deceased-don or kidney transplantation. N Engl J Med 2009; 360:7-19.
11. Moers C, Pirenne J, Paul A, Ploeg RJ. Machine perfusion or cold storage in deceased-don or kidney transplantation. N Engl J Med 2012; 366:770-771.
12. Watson CJ, Wells AC, Roberts RJ, et al. Cold machine perfusion versus static cold storage of kidneys donated after cardiac death: a UK multicenter randomized controlled trial. Am J Transplant 2010; 10:1991-1999.
13. Treckmann J, Moers C, Smits JM, et al. Machine perfusion versus cold storage for preservation of kidneys from expanded criteria donors after brain death. Transplant Int 2011; 24:548-554.
14. Gallinat A, Moers C, Treckmann J, et al. Machine perfusion versus cold storage for the preservation of kidneys from donors >65 years allocated in the Eurotransplant Senior Programme. Nephrol Dial Transplant 2012 [Epub ahead of print].
15. Jochmans I, Moers C, Smits JM, et al. Machine perfusion versus cold storage for the preservation of kidneys donated after cardiac death: a multicenter, randomized, controlled trial. Ann Surg 2010; 252:756-764.
16. Jochmans I, Moers C, Smits JM, et al. Renal resistance during machine perfusion is a factor for delayed graft function and poorer graft survival. Am J Transplant 2010; 10 (Suppl. 4):107.
17. Moers C, Varnav OC, van Heurn E, et al. The value of machine perfusion perfusate biomarkers for predicting kidney transplant outcome. Transplantation 2010; 90:966-973.
18. Jochmans I, Pirenne J. Graft quality assessment in kidney transplantation: not an exact science yet! Curr Opin Organ Transplant 2011; 16:174-179.
19. Hosgood SA, Nicholson ML. First in man renal transplantation after ex vivo normothermic perfusion. Transplantation 2011; 92:735-738.
20. Hosgood SA, Nicholson ML. Normothermic kidney preservation. Curr Opin Organ Transplant 2011; 16:169-173.
21. Monbaliu D, Brassil J. Machine perfusion of the liver: past, present, and future. Curr Opin Organ Transplant 2010; 15:160-166.
22. Monbaliu D, Heedfeld V, Liu Q, et al. Hypothermic machine perfusionofthe liver: isitmore complex than for the kidney? Transplant Proc 2011; 43:3445-3450.
23. Imber CJ, St Peter SD, Lopez de Cenarruzabeitia I, et al. Advantages of normothermic perfusion over cold storage in liver preservation. Transplantation 2002; 73:701-709.
24. Hessheimer AJ, Fondevilla C, Garcia-Valdecasas JC. Extracorporeal machine liver perfusion: are we warming up? Curr Opin Organ Transplant 2012; 17:143-147.
25. De Rougemont O, Breitenstein S, Leskosek B, et al. One hour hypothermic oxygenated perfusion (HOPE) protects nonviable liver allografts donated after cardiac death. Ann Surg 2009; 250:674-683.
26. Brockmann J, Reddy S, Coussios C, et al. Normothermic perfusion: a new paradigm for organ preservation. Ann Surg 2009; 250:1-6.
27. Fondevilla C, Hessheimer AJ, Maathuis MA, et al. Superior preservation of DCD livers with continuous normothermic perfusion. Ann Surg 2011; 254:1000-1007.
28. Jamieson RW, Zilvetti M, Roy D, et al. Hepatic steatosis and normothermic perfusion-preliminary experiments in a porcine model. Transplantation 2011; 92:289-295.
29. Guarrera JV, Henry SD, Samstein B, et al. Hypothermic machine preservation in human liver transplantation: the first clinical series. Am J Transplant 2010; 10:372-381.
30. Henry SD, Nachber E, Tulipan J, et al. Hypothermic machine preservation reduces molecular markers of ischemia/reperfusion injury in human liver transplantation. Am J Transplant 2012; 12:2477-2486.
31. Taylor MJ, Baicu S, Leman B, et al. Twenty-four hour hypothermic machine perfusion preservation of porcine pancreas facilitates processing for islet isolation. Transplant Proc 2008; 40:480-482.
32. Karcz M, Cook HT, Sibbons P, et al. An ex-vivo model for hypothermic pulsatile perfusion of porcine pancreata: hemodynamic and morphologic characteristics. Exp Clin Transplant 2010; 8:55-60.
33. Leeser DB, Bingaman AW, Poliakova L, et al. Pulsatile pump perfusion of pancreata before human islet cell isolation. Transplant Proc 2004; 36:1050-1051.
34. Jirsch DW, Fisk RL, Couves CM. Ex vivo evaluation of stored lungs. Ann Thorac Surg 1970; 10:163-168.
35. Hardesty RL, Griffith BP. Autoperfusion of the heart and lungs for preservation during distant procurement. J Thorac Cardiovasc Surg 1987; 93:11-18.
36. Steen S, Sjoberg T, Pierre L, et al. Transplantation of lungs from a nonheart-beating donor. Lancet 2001; 357:825-829.
37. Steen S, Liao Q, Wierup PN, et al. Transplantation of lungs from nonheart-beating donors after functional assessment ex vivo. Ann Thorac Surg 2003; 76:244-252.
38. Rega FR, Vandezande EJ, Jannis NC, et al. The role of leucocyte depletion in ex vivo evaluation of pulmonary grafts from (non)heart-beating donors. Perfu-sion 2003; 18 (Suppl. 1):13-21.
39. Erasmus ME, Fernhout MH, Elstrodt JM, et al. Normothermic ex vivo lung perfusion of nonheart-beating donor lungs in pigs: from pretransplant function analysis towards a 6-h machine preservation. Transpl Int 2006; 19:589-593.
40. Snell GI, Oto T, Levvey B, et al. Evaluation of techniques for lung transplantation following donation after cardiac death. Ann Thorac Surg 2006; 81:2014-2019.
41. Neyrinck A, Rega F, Jannis N, et al. Ex vivo reperfusion of human lungs declined for transplantation: a novel approach to alleviate donor organ shortage? J Heart Lung Transplant 2004; 23(S2):S173 [abstract].
42. Wierup P, Haraldsson A, Nilsson F, et al. Ex vivo evaluation of nonacceptable donor lungs. Ann Thorac Surg 2006; 81:460-466.
43. Egan TM, Haithcock JA, Nicotra WA, et al. Ex vivo evaluation of human lungs for transplant suitability. Ann Thorac Surg 2006; 81:1205-1213.
44. Cypel M, Yeung JC, Hirayama S, et al. Technique for prolonged normothermic ex vivo lung perfusion. J Heart Lung Transplant 2008; 27:1319-1325.
45. Cypel M, Rubacha M, Yeung J, et al. Normothermic ex vivo perfusion prevents lung injury compared to extended cold preservation for transplantation. Am J Transplant 2009; 9:2262-2269.
46. Ingemansson R, Eyjolfsson A, Mared L, et al. Clinical transplantation of initially rejected donor lungs after reconditioning ex vivo. Ann Thorac Surg 2009; 87:255-260.
47. Cypel M, Yeung J, Liu M, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med 2011; 364:1431-1440.
48. Zych B, Popov AF, Stavri G, et al. Early outcomes of bilateral sequential single lung transplantation after ex-vivo lung evaluation and reconditioning. J Heart Lung Transplant 2012; 31:274-281.
49. Aigner C, Slama A, Hötzenecker K, et al. Clinical ex vivo lung perfusion-pushing the limits. Am J Transplant 2012; 12:1839-1847.
50. Moradiellos FJ, Naranjo JM, Cordoba M, et al. Clinical lung transplantation after ex vivo evaluation of uncontrolled non heart-beating donors lungs: initial experience. J Heart Lung Transplant 2011; 30(4S):S38 [abstract].
51. Wallinder A, Ricksten SE, Hansson C, et al. Transplantation of initially rejected donor lungs after ex vivo lung perfusion. J Thorac Cardiovasc Surg 2012; 144:1222-1228.
52. Warnecke G, Moradiellos J, Tudorache I, et al. Normothermic perfusion of donor lungs for preservation and assessment with the organ care system lung before bilateral transplantation: a pilot study of 12 patients. Lancet 2012; 380:1851-1858.
53. Sanchez PG, Bittle GJ, Burdorf L, et al. State of art: clinical ex vivo lung perfusion: rationale, current status, and future directions. J Heart Lung Transplant 2012; 31:339-348.
54. TM). J Heart Lung Transplant 2012; 31 (4S):S115.
55. Proctor E, Parker R. Preservation of isolated heart for 72h. Br Med J 1968; 4:296-298.
56. Wicomb WN, Cooper DK, Novitzky D, Barnard CN. Cardiac transplantation following storage of the donor heart by a portable hypothermic perfusion system. Ann Thorac Surg 1984; 37:243-248.
57. Wicomb WN, Novitzky D, Cooper DK, Rose AG. Forty-eight hours hypother-mic perfusion storage of pig and baboon hearts. J Surg Res 1986; 40:276-284.
58. Wicomb WN, Cooper DK, Barnard CN. Twenty-four-hour preservation of the pig heart by a portable hypothermic perfusion system. Transplantation 1982; 34:246-250.
59. Rosenbaum DH, Peltz M, DiMaio JM, et al. Perfusion preservation versus static preservation for cardiac transplantation: effects on myocardial function and metabolism. J Heart Lung Transplant 2008; 27:93-99.
60. Ozeki T, Kwon MH, Gu J, et al. Heart preservation using continuous ex vivo perfusion improves viability and functional recovery. Circ J 2007; 71:153-159.
61. Stowe DF, Camara AK, Heisner JS, et al. Low-flow perfusion of guinea pig isolated hearts with 26 degrees C air-saturated Lifor solution for 20 h preserves function and metabolism. J Heart Lung Transplant 2008; 27:1008-1015.
62. Hassanein WH, Zellos L, Tyrrell TA, et al. Continuous perfusion of donor hearts in the beating state extends preservation time and improves recovery of function. J Thorac Cardiovasc Surg 1998; 116:821-830.
63. Garbade J, Krautz C, Aupperle H, et al. Functional, metabolic, and morphological aspects of continuous, normothermic heart preservation: effects of different preparation and perfusion techniques. Tissue Eng Part C Methods 2009; 15:275-283.
64. McCurry K, Jeevanandam V, Mihaljevic T, et al. Prospective multicenter safety and effectiveness evaluation of the organ care system device for cardiac use (PROCEED). J Heart Lung Transplant 2008; 27:S166 [abstract].
65. Tenderich G, El-Banayosy A, Rosengard B, et al. Prospective multicenter European trial to evaluate the safety and performance of the organ care system for heart transplants (PROTECT). J Heart Lung Transplant 2007; 26:S64 [abstract].
66. Monbaliu DR, Debbaut C, Hillewaert WJ, et al. Flow competition between hepatic arterial and portal venous flow during hypothermic machine perfusion preservation of porcine livers. Int J Artif Organs 2012; 35:119-131.
67. Yang B, Hosgood SA, Bagul A, et al. Erythropoietin regulates apoptosis, inflammation and tissue remodelling via caspase-3 and IL-1b in isolated hemoperfused kidneys. Eur J Pharmacol 2011; 660:420-430.
68. Monbaliu D, Vekemans K, Balligand E, et al. Multifactorial biological modulation of warm ischemia reperfusion injury in liver transplantation from nonheart-beating donors eliminates primary nonfunction and reduces bile salt toxicity. Ann Surg 2009; 250:808-817.
69. Vekemans K, Monbaliu D, Balligand E, et al. Improving the function of liver grafts exposed to warm ischemia by the Leuven drug protocol: exploring the molecular basis by microarray. Liver Transpl 2012; 18:206-218.
70. Rega FR, Wuyts WA, Vanaudenaerde BM, et al. Nebulized N-acetyl cysteine protects the pulmonary graft inside the nonheart-beating donor. J Heart Lung Transplant 2005; 24:1369-1377.
71. Geudens N, Wuyts WA, Rega FR, et al. N-acetyl cysteine attenuates the inflammatory response in warm ischemic pig lungs. J Surg Res 2008; 146:177-183.
72. Inci I, Ampollini L, Arni S, et al. Ex vivo reconditioning of marginal donor lung injured by acid aspiration. J Heart Lung Transplant 2008; 27:1229-1236.
73. Inci I, Zhai W, Arni S, et al. Fibrinolytic treatment improves the quality of lungs retrieved from nonheart-beating donors. J Heart Lung Transplant 2007; 26:1054-1060.
74. Cypel M, Liu M, Rubacha M, et al. Functional repair of human donor lungs by IL-10 gene therapy. Sci Transl Med 2009; 1:1-9.
75. English K, Mahon BP. Allogeneic mesenchymal stem cells: agents of immune modulation. J Cell Biochem 2011; 112:1963-1968.
76. Roemeling-van Rhijn M, Weimar W, Hoogduijn MJ. Mesenchymal stem cells: application for solid-organ transplantation. Curr Opin Organ Transplant 2012; 17:55-62.
77. Hoogduijn MJ, Popp FC, Grohnert A, et al. Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT). Transplantation 2010; 90:124-126.
78. Baiguera S, Jungebluth P, Mazzanti B, Macchiarini P. Mesenchymal stroma cells for tissue-engineered tissue and organ replacements. Transplant Int 2012; 25:369-382.
79. Lange C, Tögel F, Ittrich H, et al. Administered mesenchymal stem cells enhance recovery from ischemia/reperfusion-induced acute renal failure in rats. Kidney Int 2005; 68:1613-1617.
80. Tögel F, Westenfelder C. Mesenchymal stem cells: a new therapeutic tool for AKI. Nat Rev Nephrol 2010; 6:179-183.
81. Tan J, Wu W, Xu X, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 2012; 307:1169-1177.
82. Pan GZ, Yang Y, Zhang J, et al. Bone marrow mesenchymal stem cells ameliorate hepatic ischemia/reperfusion injuries via inactivation of the MEK/ERK signaling pathway in rats. J Surg Res 2012; 178:935-948.
83. Popp FC, Renner P, Eggenhofer E, et al. Mesenchymal cells as immunomo-dulators after liver transplantation. Liver Transpl 2009; 15:1192-1198.
84. Popp FC, Fillenberg B, Eggenhofer E, et al. Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation-a phase I study (MISOT-I). J Transl Med 2011; 9:124.
85. Jiang H, Qu L, Li Y, et al. Bone marrow mesenchymal stem cells reduce intestinal ischemia/reperfusion injuries in rats. J Surg Res 2011; 168:127-134.
86. Fang X, Neyrinck AP, Matthay MA, Lee JW. Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoietin-1. J Biol Chem 2010; 20:26211-26222.
87. Lee JW, Fang X, Gupta N, et al. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci USA 2009; 106:16357-16362.
88. Gotts JE, Matthay MA. Mesenchymal stem cells and acute lung injury. Crit Care Med 2011; 27:719-733.
89. Casiraghi F, Azzolini N, Cassis P, et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol 2008; 181: 3933-3946.
90. Franquesa M, Hoogduijn MJ, Baan CC. The impact of mesenchymal stem cell therapy in transplant rejection and tolerance. Curr Opin Organ Transplant 2012; 17:355-361.
91. Casiraghi F, Noris M, Remuzzi G. Immunomodulatory effect of mesenchymal stromal cells in solid organ transplantation. Curr Opin Organ Transplant 2010; 15:731-737.